This round is no longer accepting investments, but hundreds just like it are live now.

Log In

INVEST IN LIFEBRIDGE 10000 TODAY!

Breakthrough Cancer Therapy

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$23,091 Raised

REASONS TO INVEST

ABOUT

HEADQUARTERS
862 E Wildmere Ave
Longwood, FL 32750

TEAM

Peter F Travers
Peter F Travers
CEO / Managing Member

Founder & CEO 40 years of experience in entrepreneurship, with strong background in marketing and customer loyalty research. Mr. Travers earned his Bachelor’s degree in Communication from the University of Central Florida. He has started several firms from scratch, including a medical patient education company that sold training materials he produced to over 3,000 of the nation’s hospitals over a 12-year period. Mr. Travers established a marketing program that achieved over 1,000,000 viewers per year on the closed-circuit television systems of over 1,000 hospitals nationwide. Mr Travers has served has the managing Member of Loyalty Based Innovations, LLC the Intellectual Property firm holding and licensing patents, since Jan of 2015 Mr Travers has served as the managing member of Comprehensive Innovations, LLC, his personal holding company and majority owner of Lifebridge 10000, LLC since 2015 Mr Travers serves as the managing member of LifeBridge 10000, LLC Since Jan 2015. The company of this offering providing cancer therapies. Mr Travers has served has the CEO of Comprehensive Loyalty, INC since August of 2002. The firm specializes in customer loyalty and predictive models for retail site selection

Ken Watkins
Ken Watkins
Senior Engineer

Team leader for development of the LB10000 system and ongoing innovations in the area of Tumor Treating Fields. Mr. Watkins received his B.S.E.E. and M.S.E.E. from the University of New Mexico. He has over 40 years’ experience in developing new high-tech products. He held the position of Electrical Engineering Manager at Northrop Grumman Corp, where he was responsible for overseeing the work of 30 electrical engineers. Mr. Watkins carries top-secret clearance and worked on the Trident Missile while at Gulton Industries. He has also written a book on how to convert gas-powered vehicles to all electric. Mr. Watkins brings a wealth of experience and team-building knowledge to LifeBridge.

Timothy Vandermey
Timothy Vandermey
Senior Engineer

Consults on the LB10000 prototype design and ongoing innovations in the area of Tumor Treating Fields. Mr. VanderMey earned his B.S degree in Mechanical Engineering from Geneva College with Math and Electrical Engineering minors. He is the founder and president of Proton Design, a firm that provides engineering design consulting. He led a 15-member engineering department while with the Intellon Corporation. His work has achieved many patents for both him and his clients. He recently designed a medical device to measure pressure during tracheal intubation. Mr. VanderMey developed the original design for the LB10000.

Dianna LaTour

Dianna LaTour

Business Strategy Advisor

Ms. LaTour has been successful in starting and building new ventures, repositioning under-performing organizations, identifying and negotiating mergers and acquisitions for successful companies, and restarting failing businesses. She currently serves as an Operating Partner for LFE Capital, Naples, FL and Minneapolis, MN and the Managing Partner of LaTour & Associates, an international consulting firm focused on innovative business development. Previously she served as President & CEO of World Telehealth Corporation, an online healthcare company serving the G77 countries; CEO of ContourPak International, a cold therapy healthcare products company (acquired by Futuro); Founder, CEO and President of Theranetics, Inc., a physical therapy media products company (acquired by Kaiser Permanente); President & CEO of numerous tech companies. Ms. LaTour currently serves as Chairman of the Board, Earthrise Space Inc.; Board Member of Zuke Music Inc.; and Karman Space Inc.; and Board Observer for TAO Connect Inc., and Mend Software Inc. She also serves on community boards at Crummer Business School Entrepreneurial Program at Rollins College; the Regional Joint Partnership Capital Task Force for Orlando, Inc., and BizLife and Factur. Ms. LaTour holds a B.S. in Mathematics from University of California, Los Angeles, M.S. degrees in Mathematics & Behavioral Psychology from University of Southern California, and is a graduate of the Advanced Management Program at Harvard University.

Scott Hubbard

Scott Hubbard

Global market Strategist/Clinical Research Advisor

Mr. Hubbard provides advice on most aspects of LifeBridge’s business model and research efforts. He provides business contacts and will play a major role in advising the structure and organization of the Phase 1 clinical trial. Scott has over 20 years’ experience in the medical device industry. He is presently the Senior Director of Business Development/Partnerships for Merge eClinical, an IBM Company that streamlines data collection and analysis for clinical trials globally. Prior to his present position, he was the Director of Business Development, Medical Devices and Diagnostic Research for ICON plc, the fifth largest clinical research company in the world, with over 10,000 employees in 38 countries.

Lee M. Zehngebot, MD

Lee M. Zehngebot, MD

Medical Advisor

Dr. Lee Zehngebot has served as the Director of Clinical Research, Florida Hospital Cancer Institute in Orlando since 2007 and has participated as Principal Investigator and Co-Investigator on numerous clinical studies. In 2008, he helped Florida Hospital to earn a Clinical Trials Participation National Award from the American Society of Clinical Oncology (ASCO).Published in prestigious journals such as the Journal of Clinical Oncology, Cancer and Annals of Oncology; recognized with a regional award as one of the Best Doctors in America. Dr. Zehngebot has expressed an interest in being the principle investigator for our phase 1 clinical trial once FDA requirements have been met.

Avi Roop

Avi Roop

Med Device Commercialization

Avi Roop is the Chairman of the Board and CEO of Miret Surgical Inc., a Managing Member of ExoToe LLC, and a Partner with Surgical Design Innovations. His twenty-year career in surgical and interventional device markets encompasses ten years at 2 large-caps and ten years at 5 start-ups. Three of the five start-ups were sold to strategic partners; the other two are going concerns. Avi has spent fourteen years in customer-facing roles spanning senior management, corporate marketing, and product development. He possesses extensive experience in early-stage development from unmet need identification to early commercialization. During his career, he has been named on twenty-four issued US patents and more than 35 issued patents globally. Avi completed the Stanford Biodesign Fellowship supported by the Cottrell, Kauffman and Lucile Packard Foundations, received an MBA from the Haas School of Business at UC Berkeley and received a BS Mechanical Engineering from the University of Minnesota Institute of Technology.

Edward Abt

Edward Abt

Accounting

Mr. Abt has 23 years of experience in financial and accounting roles with General Electric Credit, Martin Marietta, and several non-profits. He has a business management degree from UCF and started his career after college with Mr. Travers’ first start-up as his office manager/bookkeeper. He works part-time as LifeBridge 10000’s bookkeeper. Mr. Abt has 23 years of experience in financial and accounting roles with General Electric Credit, Martin Marietta, and several non-profits.

Scott Krywick

Scott Krywick

Head Programmer

30 years of experience in commercial and DoD image processing and command & control, in the past winner of technical Emmy award for his work on High Definition video imaging

TERMS

LifeBridge 10000
Overview
PRICE PER SHARE
$1
DEADLINE
Mar 29, 2018
VALUATION
$12.14M
FUNDING GOAL
$10k - $107k
Breakdown
MIN INVESTMENT
$100
MAX INVESTMENT
$107,000
MIN NUMBER OF SHARES OFFERED
10,000
MAX NUMBER OF SHARES OFFERED
107,000
OFFERING TYPE
Equity
SHARES OFFERED
Non Voting Membership Interests

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$2,519

$989

Cash & Cash Equivalents

$404

$989

Accounts Receivable

$0

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Revenue & Sales

$0

$0

Costs of Goods Sold

$0

$0

Taxes Paid

$0

$0

Net Income

-$160,566

-$26,520

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.

ALL UPDATES

03.29.18

Thank you for investing in our mission! Campaign ends at midnight tonight pacific time.

Thank you so much for investing in our mission. We are working hard for you as we believe serving our investors is of equal importance to serving those who need a new cancer therapy. You the investor drive development and the saving of lives. Those of you who are still considering joining our effort by investing, please note the campaign closes at midnight tonight.

Please let me know if you have any questions.

Thank you

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

03.28.18

Thank you for investing in our mission! Campaign ends at midnight tonight.

Thank you so much for investing in our mission. We are working hard for you as we believe serving our investors is of equal importance to serving those who need a new cancer therapy. You the investor drive development and the saving of lives. Those of you who are still considering joining our effort by investing, please note the campaign closes at midnight tonight.

Please let me know if you have any questions.

Thank you

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

03.27.18

Let’s end this campaign by giving someone the possibility of extended high quality life today, through Tumor Treating Fields (TTF)!

 https://clinicaltrials.gov/ct2/show/NCT02973789?term=lunar

Above is a picture from NovoCure’ s open phase 3 clinical trail for Non-Small Cell Lung Cancer (NSCLC). We are working hard to develop an advanced form of TTF that is not only more effective, but is designed from the ground up to treat late stage patients with disease in multiple locations, such as the lung and liver simultaneously. One of our main goals is to bring the therapy to these people who would otherwise not benefit.

But, there are hundreds of thousands of patients that can benefit from fixed array TTF. According to the American Cancer Society over 150,000 Americans will die from NSCLC this year, and even larger numbers worldwide.  You may be able to help some of them now. If you know of someone with NSCLC please share the link above to NovoCures trial at ClinicalTrials.gov. NSCLC patients working with their doctors can see if they qualify for this important 500-person phase 3 clinical trial. Those that received TTF and followed regimen in the phase 2 trial, fared over a hundred percent better than those on chemo alone.

If you can share this information and someone gets in the NovoCure trail and receives high quality extended life, you will understand the mission of LifeBridge 10000 in a new and personal way.

Peter Travers
CEO
LifeBridge 1000   

03.26.18

The progress you have helped make possible during our campaign! 2 days left to join the team


During our time together on StartEngine your funds have helped us:

  • Make medical history by demonstrating a small 16 array prototype manipulating a tumor treating field through a human body. This first time this had ever been done.
  • Tell the story in a proof of concept video (available on StartEngine).
  • Supplied our engineers with the parts they needed to expand our prototype.
  • Helped us finalize our U.S. patent work and receive a full U.S. patent. We are so thankful for this major milestone
  • Helped us reach the final stages of a prototype large enough to treat lung cancer! (picture shown)
  •   And you saw us expand our experienced advisory board. Combined we have 225 years of experience in the medical field, 8 startups 5 of which sold to larger concerns, 2 are ongoing businesses. Our advisors are on the boards of 7 companies and are named on 37 issued patents.

You can make a difference. Invest today!

Peter F Travers
CEO


03.25.18

We know firsthand how devastating cancer can be. Help us make a difference. Invest today! Only 3 days left

03.23.18

Your investment dollars at work. Your prototype large enough to treat lung cancer.

As we speak our engineers are putting our new prototype through its paces. This prototype is larger than fixed array devices being tested on over 500 lung cancer patients in open phase 3 clinical trials.

Our device is built from the ground up to bring tumor treating field therapy to late stage patients with disease in multiple locations like the lung and liver simultaneously. You can help us get to clinical trials by investing today!  Thank you on behalf of those who have more life to live!  Only days left.

Peter Travers

CEO

LifeBridge 10000, LLC

   

03.19.18

Learn how YOU are revolutionizing the development of cancer therapies. Watch our new video now!

03.16.18

LifeBridge 10000 raises $69,000 to reach a total to date of over $359,000

We have been asked “What if you don’t raise your highest goal on StartEngine?”. LifeBridge began raising funds through a Reg D offering before beginning on StartEngine. Although we are moving our emphasis to title 3 crowdfunding, friends family and accredited investors have continued supporting our research and mission. In January of this year $50,000 came in through our Reg D offering (see below). With your investment and additional commitments, we are approaching a total of $400,000 raised.

Our desire to move to crowd funding is our belief that you are more likely to be missional moving forward. You are OK with making a decent return and giving a percentage of profits to those who cannot afford treatment. We believe our mission will bring us all more profit as we gain the respect of the medical community as a company that cares. The bottom line is our effort will continue with or without crowdfunding. We hope and pray it will be with you, as institutional investors tend to strip away mission.

Please invest today, because they have more life to live! 

03.12.18

As you know the patented device of LifeBridge 10000, LLC is about the next advanced use of Tumor Treating Fields, but listen to what Mad Money CNBC says about the base science developed by NovoCure

                     Link to Mad Money CNBC:     https://www.youtube.com/watch?v=0qAlyZhfetc

03.09.18

Let me tell you a story of how tumor treating fields can change the management of stage 4 cancer over a life span.

My wife presented in front of our radiation oncologist with significant back pain from her stage 4 cancer attacking nerves in her lower back. We had run out of chemo’s to use, so radiation was the only known way to keep the pain from becoming debilitating. My wife’s medical chart was still on paper at this point and was literally about 10 inches thick. 18 years and twelve re-occurrences of cancer made for a long history.

The doctor read silently, searching the file when a disappointing look came over his face. He said “about twelve years ago you had a breakout of cancer in your lower back and we used multiple treatments of radiation to resolve the issue. The pain you are experiencing now is in the same area. If we radiate that area again it could damage your nerves and the pain could be much worse. We should only radiate as a last resort”. Out of options is the dreaded destination of the cancer journey, but for us there was good news.

Before we get to the good news, let’s talk for a moment about a lifetime strategy for battling cancer. We learned through my wife’s 18-year battle with stage 4 breast cancer that you are going in to fight with a limited amount of ammunition. Once a certain type of ammunition is used up, you can be left without a defense. Some chemo’s have a lifetime limit to how many doses you can take, because the side effects can put you into a wheel chair or worse. As we learned above, radiating the same area twice is really discouraged, because of the nerve damage and other side effects.   

One of the problems with managing cancer is that many times it is managed from 1 re-occurrence to the next without a lifetime strategy. To be fair, that is because there have not been many options for developing a long-term plan. My wife is an example of how Tumor Treating Fields can bring about a new strategy. The day the doctor told us he did not recommend radiating Laurie’s back a second time, he also shared with us the location of the tumors causing the pain. That same day our team began building a new tumor treating field array to cover the area. One for the lower back and one in the front to create the tumor treating field. We called it the bikini array.

Within two weeks of wearing the new array the pain began to subside. Within a month the pain was gone. Tumor treating fields allowed Laurie to avoid a risky treatment. That is the point. Tumor treating fields can be used to create a long-term strategy of preserving various treatments for later use if needed. Here is another example.

Years earlier Laurie had a suspicious tiny spot on her pancreas. To biopsy it would be difficult. The procedure would require going down the throat, out the stomach, capture the sample and back out. Obviously, the doctors wanted to avoid the ordeal. So, we were asked to wait. Almost 3 full months later scans showed that the spot had gotten bigger and the biopsy was ordered. The results showed cancer. One of the most effective chemo’s was used to eliminate the tumor. Not only did Laurie have to lose her hair and go through yet another ordeal, but one our most powerful pieces of ammunition was used up. Years later when Laurie needed it more, it could not be used effectively.

If tumor treating fields were available there is a high probability we would not have had to wait those three months. The tiny tumor could have been eliminated by tumor treating fields and one of the most effective chemo’s could have been saved for later, if needed at all. Not to mention saving Laurie from going through another rough round of side effects. Tumor treating Fields have no side effects to date, only minor skin irritation. Here we are years later and fixed array tumor treating fields for pancreatic cancer is entering a phase 3 clinical trial, after proving to be over a 120% more effective than chemotherapy alone in a phase 2 trial.

Tumor treating fields can potentially change the way long term cancer is managed. Using it against new tumors when they are tiny. Not only does this avoid terrible side effects that strain the patient and whole family, but it preserves lifesaving therapies for later if needed.  

You are the key, make a difference today by investing, because they have more life to live!

Thank you for your time, please let me know if you have any questions.

Peter Travers

CEO

LifeBridge 10000, LLC

  

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into LifeBridge 10000.

JOIN THE DISCUSSION

0/2500

JY
John Young

17 INVESTMENTS

5 years ago

Peter, thank you for the detailed replies. I have just made an initial investment in LifeBridge 10000. Please answer the following: 1. When will the offering to accredited investors expire and can you provide a link to the specifics of this offering? 2. In terms of medical tourism, can you name the medical tourism destination closest to the US mainland that does not have NovoCure patent protection? 3. How do you plan on communicating with your crowdfunding shareholders in the future? 4. Have you considered an invitation only Facebook or other social media site for all your investors?

2

0













JY
John Young

17 INVESTMENTS

5 years ago

I have been following LifeBridge 1000 carefully since your presentation on Start Engine. I have a few questions: 1. You have a parallel raise for accredited investors. How much has been raised? 2. Is the prototype advanced enough to begin the production of the 14 units for the Phase 1 clinical trial? If not, how much time and capital will be required for completion of the prototype? 3. How much will it cost to produce each of the 14 units for the Phase 1 trials? Do you have a prediction of the cost per unit to the company when they are being mass produced? 4. Do you have an estimate of how long it will take to complete the Phase 1 clinical trial? 5. In your offering, you state, “Legal counsel for LifeBridge 10000 will attempt to negotiate with Novocure to allow the freedom to operate in the U.S.”. Can you discuss this statement in greater detail?

2

0













RE
Rocco ERNE

1 INVESTMENTS

5 years ago

A ton of heart strings being pulled in your story. Why? It would seem that developing a alternative cancer treatment is enough. I am not investing because your company is centered on SELLING a story and not developing a product.

1

0













AL
Ava Lemert

1 INVESTMENTS

5 years ago

Wow, what a story. I've lost my Mother to brain lymphoma, my Father-in-law to leukemia, and since then, I've had Light the Night teams, give to St. Jude, LLS, and City of Hope, but to actually be able to help bring your treatment to cancer patients suffering now, what a chance to more directly help deliver quality of life as well as extended life. I'm sharing this with my friend who is running our Sacramento LLS fundraisers and maybe not only I can invest but maybe she can help, too. God Bless you and all who are involved in LifeBridge!!

1

0













AJ
Alan Jacobson

33 INVESTMENTS

5 years ago

Thanks for the incredibly thoughtful answers! I'm quite interested for three reasons. Most importantly I can see the promise of your approach. I did some research including watching the really good TED talk on TTF and also looking at some Insurance company medical policies. Insurance companies have a high bar when it comes to expensive new treatments, and the fact that some major private plans do cover TTF because they find the science medically necessary and compelling is huge. Second, I followed the money because I know money talks when it comes to measuring the potential of a new treatment. As you said there is a tremendous amount of money going into TTF research. Third, I like the time, energy, and thoughtfulness with which you responded to me as an investor. I hope people take the time and do some research into TTF because I think this is one of the better investment opportunities right now, and a social enterprise to boot. Thanks again!

1

0













PT
Peter Travers

LifeBridge 10000

5 years ago

Question: And I imagine the goal is to get classified as a medical device and then reimbursed by insurance - and if so, how high is that hurdle, and are your projections based on realistic reimbursement rates? Answer Part 1 of 3: Our business model is a hybrid approach that has been made available by relatively recent changes in U.S. law and the global health care industry. These changes are particularly favorable to companies like ours who are serving the late stage patient who has limited options. There are several countries with westernized medicine (internationally accredited facilities) that do not require completed clinical trials to treat late stage patients. In addition, the united states now has Right to Try Laws in 36 states that allow late stage patients to receive treatment after only a phase 1 clinical trial. The old law required a completed phase 3 trial. A phase 1 trial can be completed in as little as one year. At the same time there is now a well established global medical tourism industry. Reuters reports the global medical tourism market is growing at a rate of 18.8% per year and is projected to reach USD 46.6 billion by 2021. Medical tourism is defined as the act of traveling to a different country with the intention of seeking medical treatment of some kind, which might not be accessible in the travelers’ nation of origin. The Fiscal Times estimated that 1,400,000 Americans traveled abroad for medical treatment in 2016. To learn more about medical tourism you can go to the Medical Tourism Associations web site at http://www.medicaltourismassociation.com/en/index.html .

0

0

PT
Peter Travers

LifeBridge 10000

5 years ago

Answer 3 of 3 continued: is spending tens of millions of dollars on a 500-person phase 3, Non-Small Cell Lung Cancer Trial. To have that kind of track record and confidence that TTF works, and still deny it to the people that we can help now is unthinkable. The timing is right to make a difference, together we can be a bridge of life to hundreds of thousands of people in the years ahead. Please let me know if I can answer any additional questions Sincerely Peter “Because they have more life to live” Peter F Travers CEO LifeBridge 10000, LLC www.lifebridge10000.com

0

0

PT
Peter Travers

LifeBridge 10000

5 years ago

Question: Where do payments from patients/insurance go (to you and the practice in a split of some sort?) Answer: The traditional reimbursement model for Oncologists administering chemotherapy drugs is to prescribe the drug, administer the drug and do follow-up. For this the doctor not only receives doctors visit fees, but a percentage of the cost of the chemotherapy drug. In similar fashion the doctor will prescribe our device, train patients on the use of our device, and do follow ups. For this service the doctor will receive a monthly fee from LifeBridge per active patient prescription. The payment to the physician will be dependent on payment being received from the patient. LifeBridge will process all billing and payments. The above process is also consistent with how Tumor Treating Field devices are currently being administered to Glioblastoma (Brian Cancer) and Plural Mesothelioma (lung) patients in the U.S. today.

0

0

PT
Peter Travers

LifeBridge 10000

5 years ago

Question: Are the MD practices buying or leasing the devices from you, or something in between? Answer: We believe the best way to serve the patient is to not have the doctor or the patient ever own the device. Ownership remains with LifeBridge. LifeBridge will supply 24/7 remote support, and supply onsite training personnel to oncology group practices. The device will be programed to upload its usage report daily. The report will supply self-diagnostic status reports as well. Replacement devices will be available if any issues arise. The above model allows our life saving device be constantly updated, monitored and maintained. This process is consistent with how Tumor Treating Field devices are currently being administered to Glioblastoma (Brian Cancer) and Plural Mesothelioma (lung) patients in the U.S. today.

0

0

PT
Peter Travers

LifeBridge 10000

5 years ago

Answer Part 2 of 3: The path of our business model is to run an FDA approved phase 1 clinical trial of at least 20 patients. This size study will be credible to physicians globally as to the safety of our device. We will then begin marketing our device in strategically selected foreign markets, inviting patients to receive the therapy through medical tourism. The closest country is Canada which has special access laws for late stage patients (see https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/medical-devices.html ). There are countries with even less requirements than Canada. All countries have advertising laws that must be adhered too. We will also market in the U.S. under Right to Try laws. However, we are not adding U.S. revenues into our projections, because the U.S. congress is considering a national Right to Try law with unknown provisions regarding what can and cannot be charged. Until this issue is settled we are planning on our initial revenues being through medical tourism. Regardless our device will be legal in the U.S. in the 36 states with present laws. A U.S. citizen can personally import a medical device as long has he or she documents that the device is for a continuation of a treatment begun in a foreign country, and that the device is not for resale. In addition, with the completion of a phase 1 clinical trial it will be legal to ship our device in the U.S. We are currently patent pending in all countries that allow early access to late stage patients. While our plan unfolds it will allow us to cash flow the remaining steps in the FDA approval process, namely a phase 2 and 3 clinical trial. Our plan calls for us to remain in the full FDA approval process as we begin global marketing. The reason we believe this to be viable is the size and intensity of the late stage cancer market.

0

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$23,091
INVESTORS
69
MIN INVEST
$100
VALUATION
$12.14M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.